European agency recommends approval for Sarclisa to treat multiple myeloma in EU patients.

The European Medicines Agency's committee has recommended Sarclisa for approval in the EU to treat multiple myeloma in patients ineligible for transplants. Based on the IMROZ phase 3 study, Sarclisa combined with VRd improved progression-free survival compared to VRd alone. If approved, Sarclisa would be the first anti-CD38 therapy in the EU for this use. The treatment is already approved in the US and over 50 other countries.

November 14, 2024
4 Articles